价格

LRRK2-IN-1

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

Oligonucleotide for reducing the expression of leucine-rich repeat kinase 2 (LRRK2) and its use for preventing and/or treating human diseases
US 20260043030 A1申请人: SECARNA PHARMACEUTICALS GMBH & CO KG优先权: 2022
CN
EP
US
WO
4 件公开
COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS
EP 4401735 A4申请人: LOMOND THERAPEUTICS INC优先权: 2021
EP
US
WO
4 件公开
Methods
- US 7947468 B2
  申请人: MEDICAL RES COUNCIL优先权: 2008
  CN
  US
  3 件公开
- US 2010068742 A1
  申请人: ALESSI DARIO优先权: 2009
  US
NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-D]PYRIMIDINES AS LRRK2 INHIBITORS
EP 3255049 A1申请人: PFIZER优先权: 2012
EP
COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROGENERATIVE DISEASES
US 2017035860 A1申请人: FLYNN ALEXANDER C优先权: 2016
US
Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease
US 11208412 B2申请人: DAEGU GYEONGBUK MEDICAL INNOVATION FOUND优先权: 2017
US
1, 4-DIHYDROBENZO [D] PYRAZOLO [3, 4-F] [1, 3] DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1, AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF SUCH AUTOIMMUNE DISEASES
CN 115103844 A申请人: ORIGENIS GMBH优先权: 2019
CN
Compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for treatment of e.g. Autoimmune diseases
CN 119775277 A申请人: ORIGENIS GMBH优先权: 2019
CN
MiRNA-485 inhibitors for gene upregulation
CN 115443154 A申请人: BIOSEGA LLC优先权: 2020
CN
1-pyrazolyl, 5-, 6-disubstituted indazole derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof
US 12319671 B2申请人: MERCK SHARP & DOHME LLC优先权: 2020
US

药物

LRRK2-IN-1

专利

Methods